National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.
Content by National Comprehensive Cancer Network
New Study Unlocks Important Information About How to Treat Recurring Prostate Cancer
Routine PSMA PET/CT scans could help doctors select the best treatments for long-term outcomes in patients with recurring prostate cancer after surgical removal of the prostate
NCCN Launches New Breast Cancer Genetic Testing and Treatment Tool
The National Comprehensive Cancer Network expands its interactive library of expert cancer care guidance to cover over a dozen cancer types and hereditary risk assessment
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
New resource from the National Comprehensive Cancer Network outlines how and why to access genetic counseling and testing for multiple hereditary cancers
New Hope for Early Detection and Prevention of Pancreatic Cancer
New findings suggest pathway for screening high-risk individuals for pancreatic cancer in PRECEDE study
The Impact of Immunotherapy on Populations Underrepresented in Trials
Results reinforce the need to include Black and Hispanic people in cancer trials to deliver equitable patient care
Lack of Racial Groups' Inclusion Negatively Impacts Cancer Research
Researchers call for better inclusion of men in Africa and with African ancestry to address disparities in prostate cancer outcomes
Concerns about Clinical Trial Bias from Undisclosed Censoring
Cancer researchers call for more transparency on who drops out of clinical trials and why
Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?
Four out of five cancer therapies tested in Phase III trials do not achieve meaningful benefit in prolonging survival
Recommendations for Standardizing Quality Measurements in Oncology
NCCN Quality and Outcomes Committee’s endorsements of impactful and feasible quality and outcomes measures offer opportunities to advance the quality of cancer care in America
